

**NEWS RELEASE****INNOVOTECH ANNOUNCES APPOINTMENT OF  
DR. TYLER BOONE AS COO**

**Edmonton, Alberta, April 14, 2021** – Innovotech Inc. (TSX-V, IOT) (“Innovotech” or “the Company”) is pleased to announce the appointment of Dr. Tyler Boone as Chief Operating Officer of the Company to replace Dr. Amin Omar who, after many years of productive and valued service to the Company has relocated to his homeland, the Kingdom of Jordan, where he will remain a valued advisor to Innovotech.

Dr. Boone has been with Innovotech since mid 2017 when he was hired as a Microbiologist IV. He was appointed Laboratory Manager in December 2017. Dr. Boone obtained his undergraduate degree (BSc. Honors in Microbiology) in 2006 at the University of Alberta in the Department of Biological Sciences. He stayed to earn his PhD at the University of Alberta’s Faculty of Medical Sciences, following which, he accepted a Post Doctoral Fellowship at Loyola University in Chicago where he spent five years of laboratory work primarily in the study of spore formation. Through this internal appointment we expect that the transition of the COO office to Dr. Boone will be completely seamless as he knows both our clients and our business well.

“We are privileged to be able to fill this key office internally with a scientist and manager of Dr. Boone’s calibre” said Dr. James Timourian, President of Innovotech. “We look forward to continuing to deliver our exacting contract research services to our valued clients under Dr. Boone’s watch. Our work begins and ends in our laboratories and that work is continued by him in his new role as Chief Operating Officer”.

**About Innovotech Inc:**

Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting contract research, and owning and providing proprietary devices for testing in multiple applications in microbiology and can be found online at [www.innovotech.ca](http://www.innovotech.ca).

Alan Savage  
Director & CFO  
Innovotech Inc.  
604 220-4935  
[acs@loncap.ca](mailto:acs@loncap.ca)

*This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should*

*management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.*

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.